

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT ENTERING INTO STRATEGIC COMMERCIAL PARTNERSHIP WITH TENCENT

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis, to provide latest business update to the shareholders and potential investors of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has entered into a strategic commercial partnership with Tencent Holdings Limited (a company listed on The Stock Exchange of Hong Kong Limited, stock code: 700) (“**Tencent**”), one of the world’s largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.

As part of this partnership, the Company will explore a number of capabilities and potential solutions with Tencent, including ways to engage patients and healthcare professionals in disease awareness, particularly in various cancers, kidney diseases and severe infectious diseases, which tend to disproportionately impact people in the Greater China region and have limited treatment options, resulting in significant unmet medical need. In addition, the Company and Tencent will consider options to build a one-stop patient management ecosystem that spans disease management, from diagnosis to treatment and outcomes, as well as look at ways to leverage artificial intelligence and business intelligence tools to better identify customer profiles and improve treatment adoption.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, July 12, 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.